PMC8689125_01
Comparison between baseline imaging and on-treatment imaging. 68GaPSMA-PET at baseline (A) and at 8-week (B) showing decrease of metabolism (yellow circle). Thoracic CT Scan at baseline (C) and at 12-week (D) showing disappearance of pulmonary lesions (yellow circle).
fonc-11-782166-g001.jpg
PMC8689125_01_fonc-11-782166-g001.jpg
f1
This response was maintained on the CT scan performed 12 weeks after treatment onset (Figure 1).
Comparison between baseline imaging and on-treatment imaging. 68GaPSMA-PET at baseline (A) and at 8-week on pembrolizumab alone (B) showing absence of metabolism decrease (yellow circle) and at 16-week on axitinib alone (C) showing disappearance of metabolism (yellow circle). Other metabolic lesion was not cancer lesion, but normal kidney (left) and physiological bowel metabolism (right on the picture). Abdominal CT Scan at baseline (D), at 12-week (E) showing increase in size of the lesion at the nephrectomy site (yellow circle) and at 16-week (F) showing partial response. Thoracic CT Scan at baseline (G), at 12-week (H) showing increase in size of pulmonary lesions (yellow circle) and at 16-week (I) showing partial response.
fonc-11-782166-g002.jpg
PMC8689125_02_fonc-11-782166-g002.jpg
f2
Four weeks later (16 weeks after treatment initiation), 68Ga-PSMA-PET-CT showed a disappearance of 68Ga metabolism in all metastatic lesions; that was associated with a significant decrease in size of the local lesions (from 38 to 25 mm) and of the pulmonary lesions (from 8 to 4 mm, from 9 to 2 mm and from 15 to 6 mm) (Figure 2).
PMC8689125_02
Comparison between baseline imaging and on-treatment imaging. 68GaPSMA-PET at baseline (A) and at 8-week on pembrolizumab alone (B) showing absence of metabolism decrease (yellow circle) and at 16-week on axitinib alone (C) showing disappearance of metabolism (yellow circle). Other metabolic lesion was not cancer lesion, but normal kidney (left) and physiological bowel metabolism (right on the picture). Abdominal CT Scan at baseline (D), at 12-week (E) showing increase in size of the lesion at the nephrectomy site (yellow circle) and at 16-week (F) showing partial response. Thoracic CT Scan at baseline (G), at 12-week (H) showing increase in size of pulmonary lesions (yellow circle) and at 16-week (I) showing partial response.
fonc-11-782166-g002.jpg
PMC8689125_02_fonc-11-782166-g002.jpg
f2
Four weeks later (16 weeks after treatment initiation), 68Ga-PSMA-PET-CT showed a disappearance of 68Ga metabolism in all metastatic lesions; that was associated with a significant decrease in size of the local lesions (from 38 to 25 mm) and of the pulmonary lesions (from 8 to 4 mm, from 9 to 2 mm and from 15 to 6 mm) (Figure 2).
Timeline with imaging and response to therapies in the two clinical cases.
fonc-11-782166-g003.jpg
PMC8689125_02_fonc-11-782166-g003.jpg
f3